Search the Newsreel

Sands Capital group (NASDAQ: IKT) discloses 9.3% Inhibikase stake plus large warrants

Sands Capital Life Sciences Pulse Fund II, L.P., along with related entities, has reported a beneficial ownership of 9.3% in Inhibikase Therapeutics, Inc. This stake includes 13,018,965 shares of common stock and substantial warrants for an additional 15.5 million shares, although these warrants are …

SBS Stock 12‑Month Price Target Cut to $6.86, Implies 34% Upside

The average 12-month price target for Companhia de Saneamento Basico Do Estado De Sao Paulo - Sabesp (SBSP3) stock has been revised down from $6.91 to $6.86, according to 14 analysts. This new target implies a potential upside of approximately 34% from the August …

Companhia de Saneamento Básico do Estado de São Paulo - SABESP 2026 Q2 - Results - Earnings Call Presentation

Companhia de Saneamento Básico do Estado de São Paulo - SABESP (SBS) released its Q2 2026 earnings call presentation. The company reported an EPS of $0.06, missing estimates by $0.02, while revenue of $1.97 billion (18.40% Y/Y) beat expectations by $747.58 million. The article …

Copel (ELPC) Q2 2026 Earnings Call Transcript

Image source: The Motley Fool. DATE Wed, Aug. 5, 2026 at 8:30 a.m. ET CALL PARTICIPANTS Chief Executive Officer - Daniel Slaviero Chief Financial Officer - Felipe Gutterres Vice President of Regulatory Affairs - Andre Gomes General Manager - Dennis Mulica Full Conference Call …

Companhia de saneamento Basico Do Estado De Sao Paulo - Sabesp (NYSE:SBS) Trading Down 6.8% Following Weak Earnings

Companhia de Saneamento Basico Do Estado De Sao Paulo - Sabesp (NYSE:SBS) experienced a 6.8% drop in its stock price after reporting weaker-than-expected quarterly earnings and revenue. The company missed analyst consensus estimates with earnings of $0.07 per share and revenue of $1.16 billion. …

Copel Board Approves R$706 Million Interest on Equity and 2025 Form 20-F Filing

Copel's board of directors approved the distribution of R$706 million in interest on equity to shareholders, with payment scheduled for September 30, 2026. Concurrently, the board cleared the company's 2025 Form 20-F for filing with the U.S. SEC, enhancing transparency and regulatory compliance for …

SBS Stock Slides As Traders Reprice Defensive Utility Play

Companhia de saneamento Basico Do Estado De Sao Paulo – Sabesp (SBS) stock has fallen by 8.92% due to privatization uncertainty. The stock has dropped from the $5.80 area to the mid-$4s, breaking a multi-week uptrend. Despite solid earnings and reasonable valuation, the stock's …

Oppenheimer Maintains Inhibikase Therapeutics(IKT.US) With Buy Rating, Maintains Target Price $5

Oppenheimer has reiterated its Buy rating on Inhibikase Therapeutics (IKT.US), maintaining a target price of $5. This indicates continued confidence from the firm in the company's prospects.

SID Nacional ADR earnings missed by $0.02, revenue fell short of estimates

Sabesp (NYSE: SBS) 2Q26 profit drops while revenue and capex push higher

Sabesp (NYSE: SBS) reported mixed financial results for Q2 2026, with net revenue increasing by 13.9% to R$10,209 million, driven by construction revenue and sanitation services. However, net income fell significantly by 31.4% to R$1,464 million, and adjusted net income dropped 41.2% due to …

Companhia Siderúrgica Nacional presenta sus resultados del segundo trimestre y del primer semestre de 2026

Renaissance Technologies LLC Sells 271,633 Shares of Companhia Paranaense de Energia - Copel Unsponsored ADR $ELPC

Companhia de Saneamento Básico do Estado de São Paulo - SABESP presenta sus resultados del segundo trimestre y del primer semestre de 2026

Companhia Siderúrgica Nacional: Adjusted EBITDA up 4.8% QoQ to R$2.77B, but net loss reached R$773M on higher financial costs

Companhia Siderúrgica Nacional (CSNA3) reported a 4.8% QoQ increase in Adjusted EBITDA to R$2.77 billion, driven by strong steel and cement performance. Despite a 6.6% sequential rise in net revenue, the company posted a net loss of R$773 million due to higher financial expenses. …

National Health Investors (NHI) Stock Price Sinks As SHOP Pivot Raises Doubts

National Health Investors (NHI) experienced a stock price drop after its Q2 2026 earnings release, with Funds From Operations (FFO) per share remaining broadly flat despite increased revenue and net income. The market reacted negatively to the company's pivot towards a senior housing operating …

Companhia de saneamento Basico Do Estado De Sao Paulo - Sabesp (NYSE:SBS) Releases Quarterly Earnings Results, Misses Expectations By $0.03 EPS

Companhia de Saneamento Básico do Estado de São Paulo (SABESP) (NYSE:SBS) reported its quarterly earnings, missing analyst expectations by $0.03 EPS, with actual earnings of $0.06 against an estimated $0.09. The company also fell short on revenue, reporting $1.16 billion compared to a $1.23 …

Companhia Energética de Minas Gerais - CEMIG Q2 Earnings Preview

* Companhia Energética de Minas Gerais - CEMIG (CIG [https://seekingalpha.com/symbol/CIG]) is scheduled to announce Q2 earnings results on Thursday, August 13th, after market close. * The consensus EPS estimate is $0.05, [https://seekingalpha.com/symbol/CIG/earnings/estimates] and the consensus revenue estimate is $1.74B MORE ON COMPANHIA ENERGÉTICA DE …

National Health Investors, Inc. 2026 Q2 - Results - Earnings Call Presentation (NYSE:NHI) 2026-08-11

National Health Investors, Inc. (NHI) published its 2026 Q2 earnings call presentation. The company reported EPS of $1.15, missing estimates by $3.42, and revenue of $121.32M, beating estimates by $8.81M and showing a 33.81% year-over-year increase. This presentation is part of their official financial …

Inhibikase Therapeutics Announces Second Quarter 2026 Financial Results and Highlights Recent Activity

Inhibikase Therapeutics announced its Q2 2026 financial results, reporting a net loss of $19.6 million and $159.0 million in cash and marketable securities. The company highlighted significant progress in its Phase 3 IMPROVE-PAH study for IKT-001, including regulatory approvals in 26 countries and recent …

National Health Investors: Buy The Earnings Dip And Lock In A 5.3% Yield (NYSE:NHI)

Inhibikase Q2 Results: Net Loss Widens to $19.6 Million

Inhibikase Therapeutics reported a Q2 2026 net loss of $19.6 million, or $(0.11) per share, which met analyst estimates but widened from the previous year due to increased R&D spending for its Phase 3 PAH program. The company also raised $50 million through a …

National Health Investors Inc (NHI) (Q2 2026) Earnings Call Highlights: Strategic Pivot to SHOP ...

National Health Investors Inc (NHI) reported Q2 2026 earnings, highlighting a strategic pivot towards its SHOP portfolio. The company significantly strengthened its balance sheet through asset sales and expanded its SHOP platform, despite a slight year-over-year decline in same-store SHOP NOI for legacy properties. …

National Health Investors (NYSE:NHI) Trading Down 5.2% - Here's What Happened

CSN Gets Financial Relief as $1 Billion Debt Exchange Approved

Brazil's Companhia Siderurgica Nacional (CSN) successfully completed a debt exchange, securing crucial financial relief. The move helps the company manage high financing costs amidst its struggles.

Holders Tender 77.49% of CSN’s $1.3B 2028 Notes in Exchange Offer

Companhia Siderúrgica Nacional (CSN) announced the final results of its exchange offer for outstanding 6.750% Senior Notes due 2028, with holders tendering $1,007,324,000, or 77.49%, of the $1.3 billion in notes. Tendering holders will receive $253.85 in cash and $746.15 in new 11.000% Senior …

Companhia Brasileira de Aluminio SA (BSP:CBAV3) (Q2 2026) Earnings Call Highlights: Record ...

National Health Investors (NHI) Q2 FFO Lag Estimates

National Health Investors (NHI) came out with quarterly funds from operations (FFO) of $1.19 per share, missing the Zacks Consensus Estimate of $1.26 per share. This compares to FFO of $1.22 per share a year ago. These figures are adjusted for non-recurring items. This …

National Health Investors earnings beat by $0.28, revenue fell short of estimates By Investing.com

National Health Investors (NYSE: NHI) reported Q2 EPS of $1.15, surpassing analyst estimates by $0.28, but revenue of $68.9M fell short of the consensus of $71.52M. The company's stock price has declined by 1.00% in the last three months and 1.47% in the past …

National Health Investors (NYSE:NHI) Releases FY 2026 Earnings Guidance

National Health Investors (NYSE: NHI) releases Q2 2026 investor update materials

National Health Investors (NHI) announced the release of its Q2 2026 investor update materials, including a presentation and a press release, accessible on its website. This information, furnished under Regulation FD, provides a business update for the second quarter of 2026. NHI, a self-managed …

EDGAR Filing Documents for 0000877860-26-000201

This article provides details of an EDGAR 8-K filing (SEC Accession No. 0000877860-26-000201) by NATIONAL HEALTH INVESTORS INC. The filing, dated August 10, 2026, includes Regulation FD Disclosure and Financial Statements and Exhibits, along with interactive data and numerous graphic files. It also lists …

National Health Investors (NHI) outlines Q2 2026 NOI, lease mix and debt profile

National Health Investors (NHI) has furnished supplemental information for Q2 2026, detailing its senior housing and healthcare real estate portfolio and capital structure. The self-managed REIT reported an annualized adjusted Net Operating Income (NOI) of $289.0 million, with a diversified portfolio mix across senior …

National Health Investors: Q2 Earnings Snapshot

This article is a placeholder for National Health Investors' Q2 earnings snapshot. It currently contains no substantive content beyond its title and indicates that details will follow.

National Health Investors (NYSE:NHI) Announces Earnings Results, Beats Estimates By $0.31 EPS

National Health Investors (NYSE: NHI) boosts profit, sells $560M NHC portfolio

National Health Investors (NHI) boosts earnings and reshapes portfolio with $560M NHC sale